Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Moley

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
World Journal of Surgery|January 12, 2008
Long-term outcome of reoperations for medullary thyroid carcinomaElizabeth Fialkowski, Mary DeBenedetti, Jeffrey Moley
Endocrine-Related Cancer|July 13, 2017
A comprehensive review on MEN2BFrederic Castinetti, Jeffrey Moley, Lois Mulligan, et al.
Annals of Surgical Oncology|April 12, 2011
Racial differences in survival after surgical treatment for melanomaKaren Kadela Collins, Ryan C Fields, Dadrie Baptiste, et al.
Experimental and Molecular Pathology|May 21, 2013
Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinomaJena Hudson, Eric Duncavage, Anna Tamburrino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerSamuel A Wells, Jessica E Gosnell, Robert F Gagel, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
World Journal of Surgery|January 12, 2008
Long-term outcome of reoperations for medullary thyroid carcinomaElizabeth Fialkowski, Mary DeBenedetti, Jeffrey Moley
Endocrine-Related Cancer|July 13, 2017
A comprehensive review on MEN2BFrederic Castinetti, Jeffrey Moley, Lois Mulligan, et al.
Annals of Surgical Oncology|April 12, 2011
Racial differences in survival after surgical treatment for melanomaKaren Kadela Collins, Ryan C Fields, Dadrie Baptiste, et al.
Experimental and Molecular Pathology|May 21, 2013
Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinomaJena Hudson, Eric Duncavage, Anna Tamburrino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerSamuel A Wells, Jessica E Gosnell, Robert F Gagel, et al.
Pageof 1